Viewing Study NCT03408392


Ignite Creation Date: 2025-12-24 @ 3:42 PM
Ignite Modification Date: 2025-12-26 @ 7:17 AM
Study NCT ID: NCT03408392
Status: COMPLETED
Last Update Posted: 2020-02-25
First Post: 2018-01-17
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
Sponsor: GlaxoSmithKline
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Infections, Bacterial View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Single dose View
None Oral suspension View
None Bioequivalence View
None Cefixime View
None Two-way crossover View